EMA approves Arctic Therapeutics’ trial of AT-001 for Alzheimer’s
The European Medicines Agency (EMA) has granted approval to Iceland-based Arctic Therapeutics to commence a Phase IIa trial of small-molecule…
All articles by Gullapalli Prasanna
Gullapalli Prasanna
-
-
Roche’s Phase III trial of Gazyva/Gazyvaro for SLE meets primary endpoint
Roche has reported that its Phase III ALLEGORY trial of Gazyva/Gazyvaro (obinutuzumab) in adult patients with systemic lupus erythematosus (SLE)…
-
ArkBio commences Phase II study of AK0610 for RSV prevention
Shanghai Ark Biopharmaceutical (ArkBio) has commenced a randomised Phase II study to evaluate the fully human monoclonal antibody, AK0610, for…
-
Thermo Fisher to buy Clario for $8.8bn
Thermo Fisher Scientific has reached a definitive agreement to acquire clinical trial endpoint data solutions provider Clario Holdings for $8.875bn…
-
Datavant and Indegene partner to improve trial subject recruitment
Data collaboration platform Datavant has partnered with life sciences commercialisation company Indegene to enhance recruitment of subjects for clinical studies.…
-
Kairos Pharma reports positive data from Phase II prostate cancer treatment trial
Kairos Pharma has reported encouraging interim efficacy data from its Phase II study assessing the CD105 antagonist, ENV105 (carotuximab), in…
-
AstraZeneca’s Saphnelo SC shows reduction in disease activity in SLE trial
Pre-specified interim analysis of the randomised Phase III TULIP-SC study has demonstrated that subcutaneous (SC) administration of AstraZeneca’s fully human monoclonal…
-
Osivax initiates vaccination in OVX836 trial for influenza A
Biopharmaceutical company Osivax has vaccinated the first subject in its randomised Phase IIb trial of OVX836 for influenza A. The…
-
Trially raises $4.7m to enhance trial recruitment with AI
Clinical trial recruitment platform Trially has raised $4.7m in a seed funding round and introduced its agentic AI solution, Margo,…
-
Spyre initiates dosing in Phase II trial of rheumatic disease treatment
Spyre Therapeutics has initiated dosing in its randomised Phase II SKYWAY basket trial of SPY072 in treating three rheumatic conditions:…